<DOC>
	<DOCNO>NCT02388594</DOCNO>
	<brief_summary>This triple cohort , open-label pilot study safety antiviral activity single infusion autologous CD4+ T cell genetically modify CCR5 gene Zinc Finger Nucleases SB-728mR ( ZFN Modified CD4+ T Cells ) use electroporated mRNA without prior administration two different dos cyclophosphamide .</brief_summary>
	<brief_title>A Phase I Study T-Cells Genetically Modified CCR5 Gene Zinc Finger Nucleases SB-728mR HIV-Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>HIV1 infection , document rapid HIV test FDAapproved HIV1 Enzyme Chemiluminescence Immunoassay ( E/CIA ) test kit confirm Western blot time prior study entry HIV antigen , plasma HIV1 RNA , second antibody test method rapid HIV E/CIA . Alternatively , rapid HIV test FDAapproved HIV1 Enzyme Chemiluminescence Immunoassay ( E/CIA ) test kit available , two HIV1 RNA value ≥ 2000 copies/mL least 24 hour apart perform laboratory CLIA certification , equivalent , may use document infection . On stable antiretroviral medication ( change treatment within 4 week screen visit ) willing continue current antiretroviral therapy duration study except duration 16 week analytical treatment interruption . NOTE : Subject 's ART regimen must accordance Department Health Human Services Document `` Guidelines Use Antiretroviral Agents HIV1 Infected Adults Adolescents . '' CD4+ T cell count ≥450 cells/mm3 screen ; document CD4 nadir low 200 cells/mm3 . HIV1 RNA undetectable ultrasensitive assay copies/ml obtain study screen visit within 60 day prior study screen visit perform ultrasensitive HIV1 PCR assay . All subject must receive least 18 month therapy , undetectable viral load ultrasensitive assay since month 6 therapy . Subjects intermittent isolate episode detectable lowlevel viremia ( detectable &lt; 500 copy RNA/mL ; blip ) remain eligible . Adequate venous access contraindication leukapheresis . Laboratory value obtain screen : 1 . Hemoglobin : ≥ 10.0 ( male ) ; ≥ 9.5 ( female ) g/dL 2 . Absolute neutrophil count ( ANC ) : ≥ 1000/mm3 3 . Platelet count : ≥ 100,000/mm3 4 . Serum creatinine : ≤ 1.5 mg/dL ( 133μ mol/L ) 5 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) : ≤ 2.5 time upper limit normal ( ULN ) . Subjects must willing comply studymandated evaluation ; include change antiretroviral regimen ( unless medically indicate ) 2 month step 2 undergoing analytical treatment interruption . Be male female , 18 year age old . Ability willingness subject provide inform consent . Have Karnofsky Performance Score 70 high . Have polymorphisms CCR5 ZFN target region determine Cel I snp assay screening . Acute chronic hepatitis B hepatitis C infection ( defined section 6.3.4 6.3.8 protocol ) Current prior AIDS diagnosis . History cancer malignancy , exception successfully treat basal cell squamous cell carcinoma skin History feature physical examination indicative active unstable cardiac disease hemodynamic instability . NOTE : subject history cardiac disease may participate physician 's approval . History feature physical examination indicative bleeding diathesis . Have previously treat HIV experimental vaccine within 6 month prior screen , previous gene therapy use integrate vector . Note : Subjects treat placebo HIV vaccine study exclude documentation receive placebo provide . Use chronic systemic corticosteroid , hydroxyurea , immunomodulating agent ( e.g. , interleukin2 , interferonalpha gamma , granulocyte colony stimulate factor , etc . ) within 30 day prior study screen visit . NOTE : Recent current use inhale steroid exclusionary . If subject prescribe brief course oral corticosteroid , use limit less 7 day . Use steroids apheresis immune assessment blood draw discourage affect white blood cell function . Breastfeeding , pregnant , unwilling use acceptable method birth control . Use aspirin , dyprydamole , warfarin medication likely affect platelet function aspect blood coagulation 2week period prior leukapheresis . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . Serious illness require systemic treatment and/or hospitalization within 30 day prior study screen visit . Asymptomatic baseline serum chemistry elevation LFTs , bilirubin , lipase serum creatinine due HAART medication exclusionary , opinion investigator , abnormality attributable intrinsic hepatorenal disease . Such baseline elevation must due HAART . Receipt vaccination within 30 day prior study screen visit . NOTE : It recommend subject enrol study complete routine vaccination ( hepatitis A , hepatitis B , pneumococcus , tetanus diphtheria booster ) least 30 day prior screen study . Have allergy hypersensitivity study product excipients ( human serum albumin , DMSO Dextran 40 ) . CXCR4tropic R5/X4 dualtropic HIV identify screen use DNA tropism assay .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>